SUMMARY A series of 29 children with dermatomyositis has been reviewed and the outcome compared between cases treated by us initially with a low dosage short duration course of corticosteroids, and those referred late and having had various different therapeutic regimens and usually more active and higher dosage drug schedules. There were fewer relapses and less morbidity in the low dosage short term group. It was noted also that there was no relation between the initial mode of onset or severity and the eventual outcome or course of the disease. However, pronounced skin vasculitis appeared to reflect severity of disease.
The clinical features and diagnosis of juvenile dermatomyositis have been described,1-4 and it is generally accepted that corticosteroid therapy has reduced the morbidity and mortality of the disease5-7 and that with current treatment techniques the prognosis for life and physical function is favourable.8 9 There is, however, still inconsistency in the recommendations for treatment as regards the amount and duration of treatment with drugs, and the view is often still held that a high dosage of corticosteroids is more effective than a low dosage and that it is particularly necessary in the more severe cases.
The efficacy of moderate dose steroids used for a short period has been reported previously10 and it was recommended that a moderate daily dose of prednisolone of about 1 to 1-5 mg/kg a day should be used and as soon as clinical improvement started, generally within 2 weeks, the dosage should be reduced gradually by about 2.5 mg a week. Should any symptoms of regression occur, the previous week's dose should be maintained for a further week. The There were some striking differences in details of treatment with prednisolone between the two groups. In group 1 the initial induction dose of prednisolone was 1 mg/kg a day in all cases and the disease was successfully suppressed in all. The dose was reduced once clinical improvement occurred, which was between 1 and 2 weeks in all of them, and the rate of reduction ranged from 1 to 2.5 mg/week in all but one (Case 9) patient. This patient presented some unusual features and difficulties and needed a more prolonged and somewhat different course of management. Relapses were treated with an increase in prednisolone dose adequate to suppress the symptoms and then a gradual reduction again. Seven patients in this group were off treatment within 6 to 9 months.
In group 2 the induction dose was generally higher, ranging from 1 to 3 mg/kg a day, and usually given for a longer period ranging from 1 to 15 weeks. Fourteen patients in group 2 were given some form of prolonged maintenance treatment with prednisolone, either daily or on alternate days, and total time on treatment was much longer, ranging from 12 to 84 months.
Additional immunosuppressant therapy as an adjunct to prednisolone was given to only one patient (Case 9) in group 1. In group 2, nine of the 18 patients were treated with immunosuppressants, azathioprine alone in seven, azathioprine with chlorambucil in one, and cyclophosphamide alone in the other. Only one (Case 22) received immunosuppressants (azathioprine 1-5 mg/kg a day) from the outset; the others were started from 3 
Discussion
Juvenile dermatomyositis has a characteristic clinical presentation but the onset, course, and duration may vary in relation to severity of disease and duration. Spontaneous exacerbations and remissions are well known to occur and without specific treatment about one-third of children were estimated to recover, usually within one year of onset, but death occurred in a further one-third, generally within the first 2 years, and significant morbidity in the remaining one-third from muscle atrophy, contractures, and calcinosis.12 Before the widespread use of treatment with corticosteroids there was a significant mortality and morbidity. 13 Although the use of steroids is undoubtedly beneficial, there is always a risk inherent in chronic steroid administration, and of the many secondary complications that of steroid myopathy may make interpretation of weakness difficult. It is also possible that the risk of steroid-induced gastrointestinal ulceration and perforation may be greater in dermatomyositis,14 even though gastrointestinal involvement was already documented before the use of steroids. It would therefore seem prudent to use the lowest dose of steroid which produces a good response and to reduce this dose and stop it when it is no longer necessary. However, several recent publications still advocate either high dose steroids or a prolonged maintenance dose. 41516 Comparison of the two groups of patients in this present series shows striking differences in the drug treatment and the final outcome. Those Fatal gastrointestinal complications seen in this series probably related both to the steroids and the disease. Similar fatalities have been reported by others.8 16 Severe spinal osteoporosis is probably a specifically steroid-related complication. It occurred in the boy (Case 9) in group 1 while on a very high prednisolone dosage (2 mg/kg a day).
Other immunosuppressive agents had been used in a few patients before referral. This usually reflected difficulty with management. Although their efficacy and steroid-sparing effect has been documented previously,19 20 we have not been convinced that they have made much difference in individual cases.
We have favoured the use of azathioprine as it seems to have the least toxicity, and have used it to achieve a reduction in steroid dosage only if there is steroid dependency or unacceptable steroid toxicity. Our experience with other immunosuppressive drugs-such as cyclophosphamide and methotrexate-is limited.
As in other diseases which affect the neuromuscular system and in which contractures occur, supportive therapy in addition to drug treatment is of major importance to the outcome and an intensive physiotherapy programme should form part of the management in all cases. Our programme too ill, miserable, or weak to undertake active movements, followed by active movements as soon as the child is fit enough, and mobilisation as soon as he is able to cope. Our general philosophy has been towards early mobilisation and rehabilitation. In children who feel well enough to remain ambulant in the acute phase we do not recommend any immobilisation at all. Contractures can occur early and even in the acute stage one frequently sees a 20 or 300 limited extension of joints such as elbows. This usually resolves rapidly with the general response to drug therapy and may be further helped by physiotherapy. Once fixed contractures are allowed to occur in the chronic phase of the disease they may result in longstanding disability and prevent the patient walking again even though the power of the muscles has returned sufficiently. This was the case in several of the late referral patients, whose myositis was already burnt out. 
dermatomyositis.
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